Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

  • The following term was not found in PubMed: suiny[ti].
1.

LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin.

Baira SM, Sigalapalli DK, Bathini NB, R S, Talluri MVNK.

J Pharm Biomed Anal. 2018 Sep 10;159:92-99. doi: 10.1016/j.jpba.2018.06.036. Epub 2018 Jun 28.

PMID:
29980024
2.

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus.

Chiba Y, Yamakawa T, Tsuchiya H, Oba M, Suzuki D, Danno H, Takatsuka Y, Shigematsu H, Kaneshiro M, Terauchi Y.

J Clin Med Res. 2018 Aug;10(8):648-656. doi: 10.14740/jocmr3464w. Epub 2018 Jun 27.

3.

Anagliptin prevents apoptosis of human umbilical vein endothelial cells by modulating NOX-4 signaling pathways.

Li Q, Li J, Liu Y, Zhang M, Chen C.

Biomed Pharmacother. 2018 Jul;103:1623-1631. doi: 10.1016/j.biopha.2018.04.187. Epub 2018 May 7.

PMID:
29864951
4.

Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.

Goto M, Furuta S, Yamashita S, Hashimoto H, Yano W, Inoue N, Kato N, Kaku K.

J Diabetes Investig. 2018 May 13. doi: 10.1111/jdi.12860. [Epub ahead of print]

5.

Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall.

Li Q, Zhang M, Xuan L, Liu Y, Chen C.

Free Radic Biol Med. 2018 Jun;121:105-116. doi: 10.1016/j.freeradbiomed.2018.04.580. Epub 2018 Apr 30.

PMID:
29715547
6.

Effect of Anagliptin and Sitagliptin in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: What Is the Real REASON Behind It?

Jonnalagadda VG, Char HP, Ankana PK.

Cardiovasc Drugs Ther. 2018 Jun;32(3):311. doi: 10.1007/s10557-018-6779-9. No abstract available.

PMID:
29516206
7.

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.

Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T.

Cardiovasc Drugs Ther. 2018 Feb;32(1):73-80. doi: 10.1007/s10557-018-6776-z.

8.

The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury.

Li Q, Wu X, Liu Y, Zhang M, Bai X, Chen C.

Mol Med Rep. 2017 Dec;16(6):8003-8010. doi: 10.3892/mmr.2017.7667. Epub 2017 Sep 29.

9.
10.

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.

Kurozumi A, Okada Y, Arao T, Kobayashi T, Masuda D, Yamashita S, Tanaka Y.

J Diabetes Investig. 2018 Mar;9(2):360-365. doi: 10.1111/jdi.12739. Epub 2017 Oct 3.

11.

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.

Kitada M, Tsuda SI, Konishi K, Takeda-Watanabe A, Fujii M, Kanasaki K, Nishizawa M, Nakagawa A, Koya D.

BMJ Open Diabetes Res Care. 2017 Jul 7;5(1):e000391. doi: 10.1136/bmjdrc-2017-000391. eCollection 2017. Erratum in: BMJ Open Diabetes Res Care. 2017 Sep 7;5(1):e000391corr1.

12.

Bullous pemphigoid following the replacement of vildagliptin with anagliptin.

Oya K, Fujii M, Taguchi S, Nishie W, Izumi K, Shimizu H.

J Dermatol. 2017 Oct;44(10):e238-e239. doi: 10.1111/1346-8138.13941. Epub 2017 Jul 7. No abstract available.

PMID:
28688147
13.

Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.

Ikedo T, Minami M, Kataoka H, Hayashi K, Nagata M, Fujikawa R, Higuchi S, Yasui M, Aoki T, Fukuda M, Yokode M, Miyamoto S.

J Am Heart Assoc. 2017 Jun 19;6(6). pii: e004777. doi: 10.1161/JAHA.116.004777.

14.

Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.

Yano W, Inoue N, Ito S, Itou T, Yasumura M, Yoshinaka Y, Hagita S, Goto M, Nakagawa T, Inoue K, Tanabe S, Kaku K.

J Diabetes Investig. 2017 Mar;8(2):155-160. doi: 10.1111/jdi.12593. Epub 2016 Dec 15.

15.
16.

Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.

Sato H, Kubota N, Kubota T, Takamoto I, Iwayama K, Tokuyama K, Moroi M, Sugi K, Nakaya K, Goto M, Jomori T, Kadowaki T.

Diabetologia. 2016 Nov;59(11):2426-2434. doi: 10.1007/s00125-016-4071-8. Epub 2016 Aug 15.

PMID:
27525648
17.

Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.

Tahara N, Yamagishi SI, Bekki M, Kodama N, Nakamura T, Sugiyama Y, Oshige T, Kumashiro Y, Honda A, Tahara A, Igata S, Fukumoto Y.

Curr Vasc Pharmacol. 2016;14(6):552-562.

PMID:
27357182
18.

Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.

Hirano T, Yamashita S, Takahashi M, Hashimoto H, Mori Y, Goto M.

Metabolism. 2016 Jun;65(6):893-903. doi: 10.1016/j.metabol.2016.03.010. Epub 2016 Mar 18.

PMID:
27173468
19.

Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.

Imai C, Harazaki T, Inoue S, Mochizuki K, Goda T.

J Nutr Sci Vitaminol (Tokyo). 2015;61(4):313-21. doi: 10.3177/jnsv.61.313.

20.

Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions.

Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M.

J Enzyme Inhib Med Chem. 2015 Dec;30(6):981-8. doi: 10.3109/14756366.2014.1002402. Epub 2015 Jul 6.

PMID:
26147347

Supplemental Content

Support Center